Actively Recruiting

Phase 1
Age: 18Years +
MALE
NCT06168487

Telmisartan in Prostate Cancer

Led by Tyler J Curiel · Updated on 2025-08-21

36

Participants Needed

1

Research Sites

153 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.

CONDITIONS

Official Title

Telmisartan in Prostate Cancer

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male participants aged 18 years or older
  • Able and willing to provide informed consent or have a surrogate provide consent
  • Stable prostate cancer patients not requiring immediate change in standard treatment
  • Receiving or likely to receive specific standard care agents including cabazitaxel, docetaxel (alone or plus abiraterone), olaparib, rucaparib, or talazoparib plus enzalutamide
  • ECOG performance status of 0 to 2
  • Adequate liver and kidney function
  • Standing systolic blood pressure of 110 mm Hg or higher
  • Castrate level testosterone if not on active surveillance
  • No contraindications to telmisartan, including no ACE inhibitor use within 6 weeks before starting telmisartan
  • Ability to take or have taken own blood pressure per study protocol
  • Hemoglobin above 10 gm/dl
  • Blood prostate specific antigen above 1 ng/ml at study entry
  • Able to tolerate planned blood draws
Not Eligible

You will not qualify if you...

  • Current or recent (within 30 days) use of angiotensin receptor blockers
  • Hypertensive urgency or emergency
  • Incarceration or homelessness
  • Receiving prostate cancer treatments outside the approved agents or planned changes during the study, except local radiation
  • Use of lithium therapy
  • Recent rituximab or amifostine treatment within 30 days before telmisartan
  • Use of ramapril
  • Use of digoxin without consent to monthly blood level testing

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Dartmouth Health

Lebanon, New Hampshire, United States, 03756

Actively Recruiting

Loading map...

Research Team

K

Kayla Fay

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Telmisartan in Prostate Cancer | DecenTrialz